1naresh

Array
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)
1nareshArray
(
    [urn:ac.highwire.org:guest:identity] => Array
        (
            [runtime-id] => urn:ac.highwire.org:guest:identity
            [type] => guest
            [service-id] => ajnr-ac.highwire.org
            [access-type] => Controlled
            [privilege] => Array
                (
                    [urn:ac.highwire.org:guest:privilege] => Array
                        (
                            [runtime-id] => urn:ac.highwire.org:guest:privilege
                            [type] => privilege-set
                            [privilege-set] => GUEST
                        )

                )

            [credentials] => Array
                (
                    [method] => guest
                )

        )

)

Table 1: Baseline characteristics of patients with pontine pHGG (n = 83)
Patient Characteristic No. (%) or Median (Range)
Sex 
 Male 43 (52)
 Female 40 (48)
Race 
 White 60 (72)
 Black 19 (23)
 Other 4 (5)
Age at registration (yr) 6 (0.7–17)
Histone mutation status 
 H3-3A 50 (60)
 H3C2/3 11 (13)
 Wild-type 15 (18)
 H3 K27–altered, specific gene unknown 7 (8)
Presence of enhancement 
 Yes 54
 No 25
 Unknown 4
Median follow-up time of surviving patients (mo) 10.3 (2.3–76.2)

Patient Characteristic	No. (%) or Median (Range)
Sex
Male	43 (52)
Female	40 (48)
Race
White	60 (72)
Black	19 (23)
Other	4 (5)
Age at registration (yr)	6 (0.7–17)
Histone mutation status
H3-3A	50 (60)
H3C2/3	11 (13)
Wild-type	15 (18)
H3 K27–altered, specific gene unknown	7 (8)
Presence of enhancement
Yes	54
No	25
Unknown	4
Median follow-up time of surviving patients (mo)	10.3 (2.3–76.2)